Myriad Genetics, the company originally behind tests for the cancer-associated BRCA mutations, is suing another competitor for patent infringement.

The breast cancer-associated gene may play a protective role in neural stem cells, a mouse study finds.

A judge declines Myriad Genetics’s request to block its competitors from selling BRCA tests.  

August 2013's selection of notable quotes

Myriad Genetics, the company originally behind tests for the cancer-associated BRCA mutations, is suing two competitors for patent infringement.

Last week’s Supreme Court decision to invalidate patents on human genes was a win for patients, independent researchers, and even the wider biotech industry.

The Justices have decided that isolated sequences of human DNA are not eligible for patent protection, but rules that artificial sequences can be patented.
 

As reproductive tissues age, DNA repair mechanisms become less efficient, causing genomic damage to accumulate.

The Supreme Court agrees to hear a case deciding if two cancer genes should continue to be protected by patent.

Myriad Genetics can hold patents on the BRAC1 and BRAC2 oncogenes, but not on tests comparing DNA sequences.